PE20090225A1 - Proteinas de fusion que degradan el peptido beta amiloide - Google Patents
Proteinas de fusion que degradan el peptido beta amiloideInfo
- Publication number
- PE20090225A1 PE20090225A1 PE2008000557A PE2008000557A PE20090225A1 PE 20090225 A1 PE20090225 A1 PE 20090225A1 PE 2008000557 A PE2008000557 A PE 2008000557A PE 2008000557 A PE2008000557 A PE 2008000557A PE 20090225 A1 PE20090225 A1 PE 20090225A1
- Authority
- PE
- Peru
- Prior art keywords
- fusion proteins
- amyloid peptide
- beta amyloid
- fusion protein
- peptide
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Genetics & Genomics (AREA)
- Neurosurgery (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Wood Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Toxicology (AREA)
- General Engineering & Computer Science (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
REFERIDA A UNA PROTEINA DE FUSION DE FORMULA M-A, DONDE M ES UN COMPONENTE PROTEICO QUE PROLONGA LA VIDA MEDIA DE LA PROTEINA DE FUSION TAL COMO UNA PARTE Fc DE UN ANTICUERPO IgG2 Y A ES UN COMPONENTE PROTEICO QUE CORTA EL PEPTIDO BETA AMILOIDE TAL COMO NEPRILISINA EXTRACELULAR QUE TIENE UNA SECUENCIA DE AMINOACIDOS DE SEQ ID N 1,2,3 O 4 Y DONDE DICHOS M Y A ESTAN UNIDOS POR UN CONECTOR L TAL COMO UN PEPTIDO O UN CONECTOR QUIMICO. DICHA PROTEINA DE FUSION CORTA EL PEPTIDO BETA AMILOIDE Y ES UTIL EN EL TRATAMIENTO DE LA ENFERMEDAD DE ALZHEIMER
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US90847107P | 2007-03-28 | 2007-03-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20090225A1 true PE20090225A1 (es) | 2009-04-19 |
Family
ID=39788753
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2008000557A PE20090225A1 (es) | 2007-03-28 | 2008-03-27 | Proteinas de fusion que degradan el peptido beta amiloide |
Country Status (12)
Country | Link |
---|---|
US (1) | US20080242590A1 (es) |
EP (1) | EP2139525A4 (es) |
JP (1) | JP2010522559A (es) |
CN (1) | CN101668545A (es) |
AR (1) | AR066199A1 (es) |
AU (1) | AU2008230177B2 (es) |
CA (1) | CA2681404A1 (es) |
CL (1) | CL2008000910A1 (es) |
PE (1) | PE20090225A1 (es) |
TW (1) | TW200907056A (es) |
UY (1) | UY30984A1 (es) |
WO (1) | WO2008118093A1 (es) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2765688A1 (en) * | 2009-06-19 | 2010-12-23 | Medimmune, Llc | Protease variants |
WO2011161127A1 (en) | 2010-06-21 | 2011-12-29 | Medimmune, Llc | Protease variants of human neprilysin |
WO2011160732A1 (en) | 2010-06-21 | 2011-12-29 | Medimmune, Llc. | Protease variants of human neprilysin |
US20140377319A1 (en) * | 2011-04-21 | 2014-12-25 | Washington University | Altering protein concentrations in cerebrospinal fluid and/or brain interstitial fluid |
CN103529182B (zh) * | 2012-07-06 | 2016-03-16 | 中国科学院上海生命科学研究院 | rbo/Efr3a/Efr3b基因或其蛋白在诊断和治疗阿尔茨海默病中的应用 |
EP2832854A1 (en) * | 2013-08-02 | 2015-02-04 | F. Hoffmann-La Roche AG | Method for improving the recombinant expression of a polypeptide by C-terminal fusion to human neprilysin |
AU2014298519A1 (en) * | 2013-08-02 | 2016-02-04 | F. Hoffmann-La Roche Ag | Therapeutic fusion protein |
EP3783364A3 (en) * | 2014-05-22 | 2021-05-19 | Shimadzu Corporation | Surrogate biomarker for evaluating intracerebral amyloid beta peptide accumulation and method for analysis thereof |
EP3444264A4 (en) * | 2016-04-14 | 2020-03-18 | TAO Health Life Pharma Co., Ltd. | PEPTIDE FOR AMYLOSPHEROID BINDING INHIBITION (ASPD), AND ASSESSMENT AND SCREENING METHOD |
KR102676279B1 (ko) * | 2017-01-30 | 2024-06-20 | 내션얼 리서치 카운슬 오브 캐나다 | 혈액-뇌 장벽을 관통이동하는 화합물 및 이의 용도 |
EP3604328A4 (en) | 2017-03-23 | 2021-01-06 | Hanmi Pharm. Co., Ltd. | REDUCED INSULIN ANALOGUE COMPLEX FOR INSULIN RECEPTOR AND ITS USE |
CN110241128B (zh) * | 2018-03-07 | 2020-10-02 | 上海大学 | 一种含有cbd的融合基因、细胞系、液态ecm与应用 |
CA3107349A1 (en) | 2018-07-23 | 2020-01-30 | Enclear Therapies, Inc. | Methods of treating neurological disorders |
WO2020023418A1 (en) | 2018-07-23 | 2020-01-30 | Enclear Therapies, Inc. | Methods of treating neurological disorders |
EP3952947A4 (en) | 2019-04-11 | 2024-07-03 | Enclear Therapies Inc | METHODS FOR IMPROVING CEREBRAL SPINAL FLUID AND DEVICES AND SYSTEMS THEREFOR |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5541087A (en) * | 1994-09-14 | 1996-07-30 | Fuji Immunopharmaceuticals Corporation | Expression and export technology of proteins as immunofusins |
AU758240B2 (en) * | 1998-02-25 | 2003-03-20 | Merck Patent Gmbh | Enhancing the circulating half-life of antibody-based fusion proteins |
US20020086405A1 (en) * | 2000-09-25 | 2002-07-04 | Inmaculada Silos-Santiago | 56638, a novel human neprilysin protease and uses thereof |
CA2260376A1 (en) * | 1999-02-11 | 2000-08-11 | Universite De Montreal | New metalloproteases of the neprilysin family |
US20030083277A1 (en) * | 2000-02-24 | 2003-05-01 | Hersh Louis B. | Use of insulin degrading enzyme (IDE) for the treatment of alzheimer's disease in patients |
WO2002096460A1 (en) * | 2001-05-30 | 2002-12-05 | Cornell Research Foundation, Inc. | Endopeptidase/anti-psma antibody fusion proteins for treatment of cancer |
US20050118632A1 (en) * | 2003-11-06 | 2005-06-02 | Jian Chen | Polynucleotides and polypeptides encoding a novel metalloprotease, Protease-40b |
EP1934341A1 (en) * | 2005-10-03 | 2008-06-25 | AstraZeneca AB | Fusion proteins having a modulated half-life in plasma |
-
2008
- 2008-03-26 TW TW097110852A patent/TW200907056A/zh unknown
- 2008-03-27 UY UY30984A patent/UY30984A1/es not_active Application Discontinuation
- 2008-03-27 AR ARP080101265A patent/AR066199A1/es not_active Application Discontinuation
- 2008-03-27 JP JP2010500877A patent/JP2010522559A/ja not_active Withdrawn
- 2008-03-27 AU AU2008230177A patent/AU2008230177B2/en not_active Ceased
- 2008-03-27 WO PCT/SE2008/050346 patent/WO2008118093A1/en active Application Filing
- 2008-03-27 CN CN200880010294A patent/CN101668545A/zh active Pending
- 2008-03-27 EP EP08741880A patent/EP2139525A4/en not_active Withdrawn
- 2008-03-27 PE PE2008000557A patent/PE20090225A1/es not_active Application Discontinuation
- 2008-03-27 CA CA002681404A patent/CA2681404A1/en not_active Abandoned
- 2008-03-28 CL CL2008000910A patent/CL2008000910A1/es unknown
- 2008-03-28 US US12/057,464 patent/US20080242590A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP2139525A1 (en) | 2010-01-06 |
CL2008000910A1 (es) | 2008-11-21 |
AR066199A1 (es) | 2009-08-05 |
EP2139525A4 (en) | 2010-08-18 |
US20080242590A1 (en) | 2008-10-02 |
WO2008118093A1 (en) | 2008-10-02 |
UY30984A1 (es) | 2008-10-31 |
AU2008230177B2 (en) | 2012-05-10 |
CN101668545A (zh) | 2010-03-10 |
AU2008230177A1 (en) | 2008-10-02 |
CA2681404A1 (en) | 2008-10-02 |
JP2010522559A (ja) | 2010-07-08 |
TW200907056A (en) | 2009-02-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20090225A1 (es) | Proteinas de fusion que degradan el peptido beta amiloide | |
Haney et al. | Peptide design for antimicrobial and immunomodulatory applications | |
UY31123A1 (es) | Proteinas de fusion natriureticas | |
IL195338A (en) | An antibody comprising an FC variant containing amino acid replaces d or e at position 239, a medicament containing it and its use | |
EA201590545A1 (ru) | Полипептиды, содержащие fc с измененным гликозилированием и сниженной эффекторной функцией | |
EA201100070A1 (ru) | Туберкулезный белок rv2386c, композиции и их применения | |
DK1761553T3 (da) | MHC molecule-binding tumor-associated peptides | |
PE20131334A1 (es) | Anticuerpo igg1 humanizado | |
NO20063026L (no) | Antistoffer | |
ATE527353T1 (de) | Pdgf-bindendes polypeptid aus protein a | |
CL2011003122A1 (es) | Anticuerpo que se une a la proteina tau fosforilada en la serina 422 (tau ps422), pero no se une a la tau ni al fragmento mcak fosforilado; acido nucleico que lo codifica; metodo de produccion; composicion farmaceutica; y uso util en el tratamiento de una tauopatia, tal como la enfermedad de alzheimer. | |
PE20171325A1 (es) | Polipeptidos del receptor de activina variante y uso de los mismos | |
PE20090711A1 (es) | Region constante de anticuerpo mutante | |
AR062030A1 (es) | Proteinas de fusion de exendina | |
NO20071419L (no) | Polypeptidvarianter med endret effektorfunksjon | |
NZ597692A (en) | Anti-IGF antibodies | |
DE602005008996D1 (de) | Radiofluorierte peptide | |
PL397167A1 (pl) | Przeciwnowotworowe bialko fuzyjne | |
EA201390820A1 (ru) | Слитый белок против рака | |
UA107330C2 (uk) | Туберкульозний білок rv3616c та його застосування | |
WO2007018619A3 (en) | Chimeric therapeutic agents | |
DK2007885T3 (da) | Fremgangsmåde til forøgelse af in vivo-genvindingen af terapeutiske polypeptider | |
WO2008033395A3 (en) | Melanocortin and transferrin fusion proteins | |
DE602007004110D1 (de) | Hausstaubmilbenallergen | |
MX2017010359A (es) | Cadena alfa del receptor de inmunoglobulina e (ige) de alta afinidad de fusion de fragmento cristalizable (fc). |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FD | Application declared void or lapsed |